Join Growin Stock Community!

Mdxhealth s.a.MDXH.US Overview

US StockHealthcare
(No presentation for MDXH)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

MDXH AI Insights

MDXH Overall Performance

MDXH AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

MDXH Recent Performance

0.74%

Mdxhealth s.a.

0.05%

Avg of Sector

-0.31%

S&P500

MDXH PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

MDXH Key Information

MDXH Financial Forecast

chart

Browsing restrictions can be lifted for a fee.

QuarterlyEPS ForecastQoQMaxMin
2026Q1
2026Q2
2026Q3
2026Q4
2027Q1

MDXH Profile

MDxHealth SA, a commercial-stage precision diagnostics company, provides urologic solutions in the United States, the Netherlands, Belgium, Spain, Poland, Italy, rest of European Union, and internationally. Its novel prostate cancer genomic testing solutions are SelectMDx, a non-invasive urine test; and ConfirmMDx, an epigenetic test, which provide physicians with a clinical pathway to identify clinically prostate cancer while minimizing the use of invasive procedures that are prone to complications. The company was formerly known as OncoMethylome Sciences SA and changed its name to MDxHealth SA in October 2010. MDxHealth SA was incorporated in 2003 and is headquartered in Herstal, Belgium.

Price of MDXH

MDXH FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

MDXH Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-0.63
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
1.69
PB Ratio
23.55
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
65.07%
Net Margin
-30.82%
Revenue Growth (YoY)
17.45%
Profit Growth (YoY)
24.81%
3-Year Revenue Growth
28.63%
3-Year Profit Growth
35.26%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-0.63
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
1.69
PB Ratio
23.55
Price-to-FCF
-
Gross Margin
65.07%
Net Margin
-30.82%
Revenue Growth (YoY)
17.45%
Profit Growth (YoY)
24.81%
3-Year Revenue Growth
28.63%
3-Year Profit Growth
35.26%

  • When is MDXH's latest earnings report released?

    The most recent financial report for Mdxhealth s.a. (MDXH) covers the period of 2025Q3 and was published on 2025/09/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating MDXH's short-term business performance and financial health. For the latest updates on MDXH's earnings releases, visit this page regularly.

  • What is the operating profit of MDXH?

    According to the latest financial report, Mdxhealth s.a. (MDXH) reported an Operating Profit of -2.64M with an Operating Margin of -9.63% this period, representing a growth of 56.63% compared to the same period last year. Operating Profit reflects the company's core business efficiency and cost control, making it a key indicator for evaluating operational strength and profitability.

  • How is MDXH's revenue growth?

    In the latest financial report, Mdxhealth s.a. (MDXH) announced revenue of 27.43M, with a Year-Over-Year growth rate of 17.65%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.

  • How much cash does MDXH have?

    At the end of the period, Mdxhealth s.a. (MDXH) held Total Cash and Cash Equivalents of 32.01M, accounting for 0.21 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Does MDXH go with three margins increasing?

    In the latest report, Mdxhealth s.a. (MDXH) did not achieve the “three margins increasing” benchmark, with a gross margin of 65.2%%, operating margin of -9.63%%, and net margin of -29.2%%. This demonstrates limited improvement in profitability, which is a key signal for fundamental analysis. Investors should consider margin trends alongside other financial indicators to assess MDXH's profit trajectory and future growth potential.

  • Is MDXH's EPS continuing to grow?

    According to the past four quarterly reports, Mdxhealth s.a. (MDXH)'s earnings per share (EPS) shows a steady growth trend, with the latest EPS at -1.6. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of MDXH?

    Mdxhealth s.a. (MDXH)'s Free Cash Flow (FCF) for the period is 1.4M, calculated as Operating Cash Flow minus Capital Expenditures, representing a rise of 124% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.